25 Sep 2025 | 5 Mins Read
Sun Pharma shares weighed by brokers' contrasting targets
Flipitmoney
Jefferies is bullish on Sun Pharmaceutical with a "Buy" rating and Rs 2,070 target price, expecting a 26% potential upside due to strong domestic and specialty businesses, driven by volume expansion and GLP-1 opportunities. In contrast, Nuvama issued a "Hold" rating with Rs 1,830 target price, citing flat field force productivity and future regulatory and competitive challenges.